Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Felty syndrome (FS), also known as ''super rheumatoid'' disease, is a severe form of rheumatoid arthritis (RA), characterized by a triad of RA, splenomegaly and neutropenia, resulting in susceptibility to bacterial infections.
Features include: Rheumatoid arthritis, Enlarged spleen (splenomegaly), and Decreased total neutrophil count.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 2 | Enlarged spleen (splenomegaly), Decreased total neutrophil count |
Biomarker and diagnostic research for Felty syndrome has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for Felty syndrome.
127 publications have been identified in PubMed for Felty syndrome. Kisho has analyzed 53 by research type. Research spans Review / Meta-Analysis (49%), Case Report / Case Series (26%), and Basic Science / Preclinical (9%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 26 | 49% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Felty syndrome
1 |
Rheumatoid arthritis |
Digestive system | 1 | Enlarged spleen (splenomegaly) |
Patient case studies
14 |
26% |
Laboratory research | 5 | 9% |
Testing and diagnosis research | 3 | 6% |
Other research | 2 | 4% |
Disease patterns and progression | 2 | 4% |
Clinical study results | 1 | 2% |
Yazısız H (2026). [PMID: 41948960](https://pubmed.ncbi.nlm.nih.gov/41948960/). *Turkiye Parazitol Derg*. [Diagnostic / Biomarker]
Wang C (2026). [PMID: 41839635](https://pubmed.ncbi.nlm.nih.gov/41839635/). *Zhonghua Xue Ye Xue Za Zhi*. [Review / Meta-Analysis]
Park LS (2026). [PMID: 42088197](https://pubmed.ncbi.nlm.nih.gov/42088197/). *Front Oncol*. [Case Report / Case Series]
Mocritcaia A (2026). [PMID: 41575619](https://pubmed.ncbi.nlm.nih.gov/41575619/). *Clin Rheumatol*. [Review / Meta-Analysis]
Patel R (2026). [PMID: 31536299](https://pubmed.ncbi.nlm.nih.gov/31536299/). *Unknown Journal*. [Other]
Du R (2026). [PMID: 41807677](https://pubmed.ncbi.nlm.nih.gov/41807677/). *Clin Rheumatol*. [Basic Science / Preclinical]
Baldo F (2025). [PMID: 39058514](https://pubmed.ncbi.nlm.nih.gov/39058514/). *Rheumatology (Oxford)*. [Review / Meta-Analysis]
Shahini E (2025). [PMID: 40539059](https://pubmed.ncbi.nlm.nih.gov/40539059/). *Front Immunol*. [Case Report / Case Series]
Wan C (2025). [PMID: 40295304](https://pubmed.ncbi.nlm.nih.gov/40295304/). *Medicine (Baltimore)*. [Case Report / Case Series]
Yang H (2025). [PMID: 40255577](https://pubmed.ncbi.nlm.nih.gov/40255577/). *Front Pharmacol*. [Case Report / Case Series]